Utrobin Tablet

Introduction

Solifenacin succinate is a medication primarily used to treat overactive bladder (OAB) with symptoms of urinary frequency, urgency, and incontinence. It is an anticholinergic agent that works by affecting the bladder's detrusor muscle to reduce involuntary contractions. Solifenacin is marketed under various brand names and is usually taken orally in tablet form.

Uses

Solifenacin succinate is prescribed for:

Management of overactive bladder symptoms, including urinary urgency, frequency, and urge incontinence.
Improvement of symptoms related to detrusor overactivity and bladder control issues.

Brand Name	Utrobin
Type	Tablet
Weight	5 mg
Generic	Solifenacin Succinate
Manufacturer	UniMed UniHealth
Available in	English বাংলা

Mechanism of Action

Solifenacin succinate acts as a competitive antagonist at muscarinic acetylcholine receptors, particularly M3 receptors, which are involved in the contraction of the bladder detrusor muscle. By blocking these receptors, solifenacin reduces involuntary bladder contractions and increases bladder capacity, thereby decreasing the symptoms of overactive bladder.

How Long Does It Take to Work?

The onset of action for solifenacin succinate can vary, but patients may begin to notice improvements in symptoms within 1 to 2 weeks of starting treatment. Optimal therapeutic effects are usually observed after 4 to 6 weeks of consistent use.

Absorption

Solifenacin succinate is well absorbed after oral administration, with peak plasma concentrations typically occurring within 3 to 8 hours. The drug has good oral bioavailability, and its absorption is not significantly affected by food.

Route of Elimination

Solifenacin is primarily metabolized in the liver by the cytochrome P450 enzyme system, mainly CYP3A4. The drug and its metabolites are excreted via the urine and feces, with a small amount excreted unchanged in the urine.

Dosage

The recommended dose for adults and the elderly: Solifenacin Succinate 5 mg once daily. If needed, the dose may be increased to Solifenacin Succinate 10 mg once daily.

Use in children: Safety and effectiveness in children have not yet been established. Therefore, Solifenacin Succinate should not be used in children.

The recommended dosage of solifenacin succinate is:

Initial dose: 5 mg once daily.
Maximum dose: 10 mg once daily, depending on individual response and tolerability.

Dosage adjustments may be necessary for patients with hepatic impairment or those taking other medications that affect CYP3A4 activity.

Administration

Solifenacin succinate is administered orally in the form of tablets. It should be taken with a glass of water and can be taken with or without food. The tablets should be swallowed whole and not crushed or chewed.

Side Effects

Common side effects of solifenacin succinate include:

Dry mouth
Constipation
Blurred vision
Dizziness

Serious side effects may include:

Severe allergic reactions, such as rash or swelling
Urinary retention
Severe gastrointestinal symptoms

Toxicity

Signs of toxicity may include severe anticholinergic effects such as extreme dry mouth, severe constipation, or urinary retention. In cases of overdose, symptoms may include confusion, agitation, hallucinations, or tachycardia. Immediate medical attention is required in cases of suspected overdose.

Precautions

Precautions include:

Use with caution in patients with a history of gastrointestinal obstruction, bladder outlet obstruction, or severe renal or hepatic impairment.
Monitor for signs of urinary retention and adjust dosage as necessary.
Patients with a history of angle-closure glaucoma should be monitored closely.

Interaction

Solifenacin may interact with other medications, including:

CYP3A4 inhibitors (e.g., ketoconazole, itraconazole), which may increase solifenacin levels.
CYP3A4 inducers (e.g., rifampin, carbamazepine), which may decrease solifenacin levels.

Disease Interaction

Solifenacin should be used with caution in patients with:

Severe hepatic or renal impairment, as dosage adjustments may be required.
Gastrointestinal disorders that could be exacerbated by anticholinergic effects.
Glaucoma, particularly in patients with angle-closure glaucoma.

Drug Interaction

Drug interactions include:

Potential interactions with other anticholinergic drugs, which may enhance side effects.
Interactions with drugs that affect the CYP3A4 enzyme system, which may alter solifenacin metabolism.

Consult with a healthcare provider regarding potential drug interactions.

Food Interactions

There are no significant food interactions with solifenacin succinate. The drug can be taken with or without food, but it is advisable to maintain a consistent pattern to avoid variability in absorption.

Pregnancy Use

Solifenacin succinate is classified as Category C during pregnancy. Animal studies have shown adverse effects, and there are no well-controlled studies in pregnant women. It should be used during pregnancy only if the potential benefits justify the potential risks to the fetus.

Lactation Use

It is not known if solifenacin succinate is excreted in breast milk. Caution is advised if the drug is used during lactation. Alternative treatments may be considered to avoid potential exposure to the infant.

Acute Overdose

In cases of acute overdose, symptoms may include severe anticholinergic effects such as dry mouth, confusion, agitation, or urinary retention. Treatment involves supportive care and symptomatic management. Activated charcoal may be administered if the overdose is recent.

Contraindication

Solifenacin succinate is contraindicated in patients with:

Severe hepatic impairment.
Severe renal impairment without proper dose adjustment.
Urinary retention or bladder outlet obstruction.
Known hypersensitivity to solifenacin or any of its components.

Use Direction

Take solifenacin succinate exactly as prescribed by a healthcare provider. The usual dose is 5 mg once daily, which may be increased to 10 mg based on individual response and tolerance. Do not exceed the recommended dose and consult your healthcare provider before making any changes to the dosage.

Storage Conditions

Store solifenacin succinate at room temperature, away from moisture and heat. Keep the medication in its original container, tightly closed, and out of reach of children. Do not use past the expiration date printed on the packaging.

Volume of Distribution

The volume of distribution for solifenacin succinate is approximately 6 to 7 L/kg, reflecting its distribution throughout body tissues after systemic absorption.

Half Life

The elimination half-life of solifenacin succinate is approximately 45 to 68 hours. This long half-life supports once-daily dosing and contributes to sustained therapeutic effects.

Clearance

The clearance of solifenacin succinate is primarily hepatic, with the drug being metabolized by the liver. The renal clearance of unchanged drug is minimal, but dose adjustments may be required in patients with significant hepatic or renal impairment.

See in details version Utrobin Tablet 5 mg also Utrobin Tablet 5 mg in bangla